Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of UTRN. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of UTRN. Methods for modulating expression of UTRN using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of UTRN.
Type:
Application
Filed:
May 16, 2013
Publication date:
April 9, 2015
Applicants:
RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachussetts General Hospital
Inventors:
Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
Abstract: Methods of activating ATIII in situ in a blood product are disclosed, as is the use of such methods and blood products in treating infectious diseases, inflammatory disorders and diseases or conditions that are mediated by thrombin activation.
Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are calls which express the chimeric receptors and DNA encoding the chimeric receptors.
Type:
Grant
Filed:
February 24, 1995
Date of Patent:
December 21, 1999
Assignee:
The Massachussetts General Hospital
Inventors:
Brian Seed, Charles Romeo, Waldemar Kolanus